An interventional study of Lacticaseibacillus paracasei in Subjective Cognitive Decline (SCD), sponsored by Chi-Chang Huang. Completed at 1 site in Taiwan. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Chi-Chang Huang · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Cognitive Dysfunction with a site in Taiwan — 24 open to participants now, 29 under way, 3 of them phase 3. Cognitive Dysfunction · Taiwan.
Among the 111 studies in Cognitive Dysfunction with a site in Taiwan, this one is the 69th largest by enrollment of the 94 interventional ones that give a count, is one of 14 that started in 2025, is one of 78 with no phase, and was the 98th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →24 of the 111 studies in Cognitive Dysfunction with a site in Taiwan are open now. Recruiting first, the newest first:
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 30–85
Eli Lilly and Company · Sites in Taiwan, United States, Japan and 1 more country
Ages 55–85
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Taiwan, Australia, Austria and 14 more countries
Ages 18+
Cheng-Hsin General Hospital · Sites in Taiwan
Ages 65–90
National Sun Yat-sen University · Sites in Taiwan
Ages 65+ · Healthy volunteers
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 62 across the 94 interventional studies, 192 across the 17 observational. Of the 60 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 111 have an industry lead sponsor. The 10 most frequent:
Chi-Chang Huang is the lead sponsor of 5 studies on the registry; none are open to participants now.
Chi-Chang Huang has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
5 of the studies in Cognitive Dysfunction with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07358598National Sun Yat-sen UniversityEye Movement Parameters and Cognitive Functions in Older Adults | 2026-12-31 |
| NCT05830903National Taiwan University HospitalDevelop a Novel Occupational Training Program for Schizophrenia Patients Based on Virtual Reality Techniques | 2026-12-31 |
| NCT06902181China Medical University HospitalObservation of Inhalation of CXMCI-01 Essential Oil on Patients With Mild Cognitive Impairment | 2027-02 |
| NCT06467539Chang Gung Memorial HospitalNovel Augmentation of DAOIB and Antioxidant for Early Dementia | 2027-05 |
| NCT05448768Chang Gung Memorial HospitalCognitive Effects and Potential Mechanisms of TBS in Subjects With MCI | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 111 studies in Cognitive Dysfunction with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.
Lacticaseibacillus paracasei PS23 (PS23) is a specific strain of probiotic bacteria known for its potential health benefits, particularly in the context of aging and muscle health. Research suggests that it may improve cognitive function, reduce age-related muscle loss, and modulate the gut microbiota. Probiotic supplements like PS23 are being explored as potential therapeutic agents for age-related cognitive deficits. A prior study showed that PS23 supplementation delayed age-related cognitive decline in mice. Additionally, PS23 has shown antidepressant-like effects and has been found to enhance physical performance and promote muscle recovery following injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lacticaseibacillus paracasei PS23 one capsule daily for 12 weeks
Dietary Supplement: Lacticaseibacillus paracasei
one capsule daily for 12 weeks
Also known as: PS23
Neuropsychological measures Changes in CANTAB® in 40 subjects after probiotic intervention
Cambridge Neuropsychological Test Automated Battery (CANTAB®) includes computerized tests that are correlated to neural networks and have demonstrated high sensitivity in detecting changes in neuropsychological performance.
Time frame: baseline to 12 weeks assessed
Changes in Chinese version of Trail Making Test (TMT) in 40 subjects after probiotic intervention
The Trail Making Task (TMT) is a neuropsychological test consisting of two parts that assesses executive function, visual attention, speed of processing, and cognitive flexibility. In Part A, the participant connects 25 numbered circles in sequential numerical order (1 to 25) as quickly and accurately as possible. TMT-B with sequential numbers in the Chinese characters substituting for the English alphabetical sequence, replaced numbers and letters of the TMT-B by circles and squares with numbers, modified the TMT-B with the Chinese zodiacs substituting for the English alphabet
Time frame: baseline to 12 weeks assessed
Changes in Chinese version of Stroop color words test(SCWT) in 40 subjects after probiotic intervention
The Stroop Color Words test (SCWT) was used to evaluate the dominant inhibition in executive function
Time frame: baseline to 12 weeks assessed
Changes in Geriatric Depression Scale in 40 subjects after probiotic intervention
The Geriatric Depression Scale (GDS) is a screening tool for depression in older adults (55+), consisting of a short, yes/no questionnaire about feelings over the past week. Scores range between 0 and 30 points. Higher scores indicate more severe depressive symptoms.
Time frame: baseline to 12 weeks assessed
Changes in Anxiety Disorder Assessment (GAD-7) in 40 subjects after probiotic intervention
The Generalised Anxiety Disorder Assessment (GAD-7) is a seven-item instrument that is used to measure or assess the severity of generalized anxiety disorder (GAD). Each item asks the individual to rate the severity of his or her symptoms over the past two weeks. Response options include "not at all", "several days", "more than half the days" and "nearly every day"
Time frame: baseline to 12 weeks assessed
Changes in The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 (QLESQ-16) in 40 subjects after probiotic intervention
The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 is a valid, reliable self-report instrument for assessing quality of life. The minimum raw score on the Q-LES-Q-16 is 14, and the maximum score is 70, higher scores mean a better outcome.
Time frame: baseline to 12 weeks assessed
Changes in Patient Global Impression scales of Improvement rated by patient (PGI-C) in 40 subjects after probiotic intervention
The PGIC consists of one item taken from the clinical global impression and adapted to the patient. The minimum total score possible is 1 and the maximum total score possible is 7. Higher values represent a worse outcome.
Time frame: baseline to 12 weeks assessed
Changes in pTau-217 in 40 subjects after probiotic intervention
Recent, research studies have shown that plasma levels of p-Tau 217 are elevated in AD patients1,2. Additionally, it has been demonstrated that plasma p-Tau 217 levels are increased in the early stages of the AD continuum and are correlated with amyloid-PET positivity.
Time frame: baseline to 12 weeks assessed
Changes in Plasma Aβ40 and Aβ42 in 40 subjects after probiotic intervention
Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum
Time frame: baseline to 12 weeks assessed
Changes in Brain-derived neurotrophic factor (BDNF) in 40 subjects after probiotic intervention
Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal survival and growth, serves as a neurotransmitter modulator, and participates in neuronal plasticity, which is essential for learning and memory.
Time frame: baseline to 12 weeks assessed
Changes in Glial Fibrillary Acidic Protein (GFAP) in 40 subjects after probiotic intervention
Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer's disease (AD).
Time frame: baseline to 12 weeks assessed
Changes in Neurofilament Light (NfL) in 40 subjects after probiotic intervention
Neurofilament light chain (NfL) is a structural protein that normally helps support the shape and function of brain cells. In Alzheimer's disease (AD), brain cells are damaged, which causes the brain to shrink (atrophy), and symptoms such as declining cognition to occur.
Time frame: baseline to 12 weeks assessed
Changes in Mandarin Subjective Cognitive Decline Scale (SCDS) in 40 subjects after probiotic intervention
Self-reported questionnaire consisting of 14 items assessing perceived decline in memory, attention, language, planning, orientation, and other cognitive domains. Responses are typically rated on a Likert scale (e.g., 0 = "Never" to 4 = "Very frequently"), with total scores ranging from 0 to 56-higher scores indicate greater subjective cognitive complaints.
Time frame: screening, baseline to 12 weeks assessed
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Jan 2026, 3 months.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 3 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Aug 2026 → Jan 2026 and completion Dec 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lacticaseibacillus paracasei
Chi-Chang Huang